




RealRate

PHARMACEUTICAL 2017

CHINOOK THERAPEUTICS INC. Rank 137 of 292





RealRate

PHARMACEUTICAL 2017

CHINOOK THERAPEUTICS INC. Rank 137 of 292



The relative strengths and weaknesses of CHINOOK THERAPEUTICS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CHINOOK THERAPEUTICS INC. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 43% points. The greatest weakness of CHINOOK THERAPEUTICS INC. is the variable Other Liabilities, reducing the Economic Capital Ratio by 122% points.

The company's Economic Capital Ratio, given in the ranking table, is 92%, being 89% points above the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	354,764
Cost of Goods Sold	0
Intangible Assets	35,485
Liabilities, Current	30,632
Liabilities, Non-Current	1,109
Other Assets	21,978
Other Compr. Net Income	-1,345
Other Expenses	22,013
Other Liabilities	179,650
Other Net Income	2,179
Other Revenues	50,681
Property and Equipment	26,384
Research and Development	87,718
Selling, General and Administrative Expense	34,277

Output Variable	Value in 1000 USD
Assets	438,611
Liabilities	211,391
Expenses	144,008
Revenues	50,681
Stockholders Equity	227,220
Net Income	-91,148
Comprehensive Net Income	-91,820
Economic Capital Ratio	92%